An open label, repeat dose, dose escalation study conducted in Parkinson's disease patients to characterize the pharmacokinetics and effect of food on ropinirole prolonged release (PR/CR [controlled release]) 12mg tablets

Trial Profile

An open label, repeat dose, dose escalation study conducted in Parkinson's disease patients to characterize the pharmacokinetics and effect of food on ropinirole prolonged release (PR/CR [controlled release]) 12mg tablets

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Ropinirole (Primary)
  • Indications Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 Nov 2007 Status changed from initiated to completed.
    • 21 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top